Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-'408 TE ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-'408TEV-' ...

Your place to grow and call home. Join an innovative college experience offering a comprehensive education for individuals with intellectual and developmental disabilities. Through BUILD, you’ll ...

A six-state pilot program will target 'wasteful care' under Medicare Medicare programs in six states will face prior authorizations under a new pilot program. Traditional Medicare in six states will ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

The best antivirus software intercepts potential viruses before they are downloaded and executed on your device, helping to protect your from data theft, device lockout, identity theft, and other ...

The increasing network integration of industrial control systems amplifies the risk of cyberattacks on Programmable Logic Controllers (PLCs). In particular, the weak authentication of industrial ...

Dr. JeFreda R. Brown is a financial consultant, Certified Financial Education Instructor, and researcher who has assisted thousands of clients over a more than two-decade career. She is the CEO of ...

Jan. 22, 2026 Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of the disease. An experimental antibody targets a protein that ...